-
Pfizer asked the FDA to authorize emergency use of the experimental pill, which has been shown to significantly cut the rate of hospitalizations and deaths among people with coronavirus infections.
-
Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population.
-
Doctors and hospitals are facing more demands for the drug, which has been used for decades to treat river blindness, scabies and even head lice but has not been approved to treat COVID-19.
-
Based on the strength of the trial's results, Pfizer says it will ask the FDA for emergency use authorization rather than enroll more people for clinical trials.
-
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment.
-
If approved for use, the pills would add an easy-to-use weapon to the arsenal against the coronavirus pandemic.
-
The pharmaceutical company announced that its experimental pill reduced hospitalizations and deaths by half in people infected with the coronavirus. The findings are not peer reviewed.
-
At least three promising antiviral treatments for COVID-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
-
Gov. Ron DeSantis said the state will receive 3,000 doses of sotrovimab, which received emergency use authorization in May, as the Biden administration begins rationing antibody treatments to Florida.
-
With the surge in cases, one treatment for extremely sick patients is getting really hard to find. It's called extracorporeal membrane oxygenation, and it's a bypass machine for the heart and lungs.